-
T137617-5gTerfenadine has been used to study the role of histamine in itch related to proteinase-activated receptors (PARs) in mice. Terfenadine has also been used to block histamine receptor type 1 to study the pathogenesis of 2,4-dinitrobenzene sulfonic
-
T424474-1mlTeriparatide acetate.
-
T424890-1mlUsually used for dopamine uptake assays in mouse brain cells,and also has been used for non-specific binding assays in postnuclear supernatants derived from PC-12 and CV-1 cells.
-
T275454-100mgStore at 2-8°C;Keep sealing condition ,The product can be stored for up to 24 months.
-
T275454-10mgStore at 2-8°C;Keep sealing condition ,The product can be stored for up to 24 months.
-
T275454-25mgStore at 2-8°C;Keep sealing condition ,The product can be stored for up to 24 months.
-
T275454-50mgStore at 2-8°C;Keep sealing condition ,The product can be stored for up to 24 months.
-
T125095-1gTicagrelor(AZD-6140) is the first reversibly binding oral P2Y12 receptor antagonist(Ki= 2 nM), also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.A reversible antagonist of the platelet purinergic P2Y12
-
T125095-250mgTicagrelor(AZD-6140) is the first reversibly binding oral P2Y12 receptor antagonist(Ki= 2 nM), also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.A reversible antagonist of the platelet purinergic P2Y12
-
T125095-25mgTicagrelor(AZD-6140) is the first reversibly binding oral P2Y12 receptor antagonist(Ki= 2 nM), also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.A reversible antagonist of the platelet purinergic P2Y12
-
T125095-500mgTicagrelor(AZD-6140) is the first reversibly binding oral P2Y12 receptor antagonist(Ki= 2 nM), also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.A reversible antagonist of the platelet purinergic P2Y12
-
T125095-5gTicagrelor(AZD-6140) is the first reversibly binding oral P2Y12 receptor antagonist(Ki= 2 nM), also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.A reversible antagonist of the platelet purinergic P2Y12